Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Genomics & Proteomics Research

Rajani Kanth Vangala's Biography

Rajani Kanth Vangala, Director of Research, Thrombosis Research Institute

Dr. Rajani Kanth Vangala, finished his Ph.D in Human Biology specializing on Hematolo-oncology from Department of Medicine III, Ludwig Maximillians University, Munich, Germany followed by post doctoral research at Center for Genomics and Bioinformatics, Karolinska Institute, Stockholm, Sweden working on developing Karolinska-Institutet microarray chip and novel computational algorithms for microarray data analysis. After his post doctoral work, he joined Department of Hematology, Imperial College London, UK as senior researcher and worked on stem cell therapy models and DNA repair mechanisms in acute and chronic myeloid leukemias. He was also awarded the technology entrepreneur fellowship for business management studies by Tanaka Business School, Imperial College London. Further to this experience, he started a company named Innovo Biologicals Pvt. Ltd. focusing on molecular diagnostics and sold it to venture capital company and joined Institute of Bioinformatics and Applied Biotechnology, Bangalore as faculty before moving to Thrombosis Research Institute (TRI), Bangalore. He is presently the Director of Research and his work focuses on identification of biomarkers for translation to drug development and clinical utility using integrative translational informatics, genomics, proteomics and nanotechnology

Rajani  Kanth Vangala Image

Integrative Genomics and Proteomics for Linking Molecular and Clinical Worlds

Thursday, 28 May 2015 at 15:50

Add to Calendar ▼2015-05-28 15:50:002015-05-28 16:50:00Europe/LondonIntegrative Genomics and Proteomics for Linking Molecular and Clinical WorldsGenomics and Proteomics Research in

This presentation will discuss an integrative translational research strategy which utilizes the molecular networks to reconcile the genotypes and phenotypes. This talk will also highlights the successful integration of the disease phenotypes with molecular networks to elucidate the transcriptional regulation and identification followed by validation of biomarkers in coronary artery disease. In order to enable the participatory, preventive and precision medicine, how nanotechnology is used to develop novel technology platforms from bio-specimen collection, storage to assay development will be described in this presentation.

Add to Calendar ▼2015-05-28 00:00:002015-05-29 00:00:00Europe/LondonGenomics and Proteomics ResearchGenomics and Proteomics Research in